Navigation Links
Fulgent Therapeutics Announces Their Comprehensive Hereditary Cancer Test Including BRCA1 and BRCA2 Analysis
Date:6/14/2013

Temple City, CA (PRWEB) June 14, 2013

Fulgent Therapeutics LLC, a CLIA Certified Laboratory, announces the inclusion of BRCA1 and BRCA2 analysis to its Hereditary Cancer Panel. Fulgent Therapeutics is excited to add these key targets, making it the most comprehensive test for cancer risk assessment available.

Fulgent Therapeutics Hereditary Cancer Panel detects mutations in 49 known cancer predisposition genes, now including BRCA1 and BRCA2. “We use well defined processes, robust bioinformatics, and Next Generation Sequencing to provide our clients with a comprehensive look at a true myriad of genes,” according to Dr. Harry Gao, Lab Director for Fulgent Therapeutics.

Personalized medicine demands that we examine diseases in new ways and deploy innovative tools to view all angles of the patient’s health and potential diseases. Fulgent Therapeutics Hereditary Cancer Panel provides patients and physicians with the information to assess their risks and guide their care. “Making molecular diagnostics more comprehensive and at the same time more affordable is our goal,” says Dr. Gao.

Fulgent Therapeutics president, Ming Hsieh stated, “We agree with the Supreme Court’s decision and we look forward to providing physicians with better tools and more options to help their patients."

Fulgent Therapeutics is currently working on panels for more than just cancer. The Next Generation panels for many inherited disease including cardiology, pediatrics, and neurology will provide physicians with more information than previously available.

The release date for the Hereditary Cancer Panel, including BRCA1 and BRCA2, will be available July 8, 2013. Fulgent Therapeutics anticipates that it will provide another first to the industry by getting the 49-gene panel’s price under $3,000.

Additional information: info(at)fulgent-therapeutics(dot)com or 626-350-0537 x106.

About Fulgent Therapeutics LLC: Founded in 2011, Fulgent Therapeutics, LLC is a pharmaceutical and Next Generation molecular diagnostics company focusing on developing and commercializing innovative cancer therapeutics and Next Generation diagnostics. The company has a number of improved generic and innovated drug candidates in its product pipeline for treating a broad range of cancers including those of the breast, lung, ovary, colon, and pancreas. In addition, Fulgent Therapeutics has developed an innovative line of Next Generation diagnostics for both somatic and hereditary diseases.

Fulgent Therapeutics LLC
4978 Santa Anita Ave, Ste 205
Temple City, CA
91780

Read the full story at http://www.prweb.com/releases/2013/6/prweb10833921.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Mainz University obtains new CRC Nanodimensional polymer therapeutics for tumor therapy
2. MDA Awards Valerion Therapeutics $1.2 Million to Continue Myotubular Myopathy Research
3. Corena Therapeutics Launched Coresatin, a Nonsteroidal Cream Used to Treat Critical Skin Conditions and Infections
4. Global Peptide Therapeutics Market - New Market Research Report Published by Transparency Market Research
5. Liver Diseases Therapeutics Market - New Industry Research Report Published by Transparency Market Research
6. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
7. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
8. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
9. Research shows potential of microneedles to target therapeutics to the back of the eye
10. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
11. FORMA Therapeutics teams with TGen Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Remember the ... time. , According to Perry A~, author of “Calcium Bentonite Clay” the health ... key role in balancing and detoxifying the body. , A former motivational speaker, Perry ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Guruji Mahendra ... 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... happiness. Mahendra Trivedi is known by over 250,000 people from over 40 different ...
(Date:2/7/2016)... , ... February 07, 2016 , ... Women's Excellence staff, ... Wear Red Day. National Wear Red Day is the first Friday each February ... disease and stroke cause 1 in 3 deaths among women each year – more ...
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... US ... Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ultimate organizations, ... Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 CBG Technologies, a U.S. company, ... Recycling Systems, specifically designed for precision parts cleaning. ... and existing vapor degreasers, parts washers and ultrasonic ... continuous recycling and recovers 100% of the solvent ... --> Precision parts manufacturers benefit from this ...
(Date:2/8/2016)... Feb. 8, 2016  Neurocrine Biosciences, Inc. (Nasdaq: ... its fourth quarter and year-end 2015 results after the ... will then host a live conference call and webcast ... update Thursday afternoon, February 11, 2016 at 4:30 p.m. ... . --> http://www.neurocrine.com . --> ...
(Date:2/8/2016)... ISELIN, N.J. , Feb. 8, 2016 ... ), a medical device company focused on ... technologies, today announced today announced that it ... on Wednesday, February 17, 2015 at 9:00 ... and to discuss its corporate strategy, advancements ...
Breaking Medicine Technology: